Active, not recruitingNCT06952465
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Studying DITRA
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol Myers SquibbBristol-Myers Squibb
- Intervention
- Deucravacitinib(drug)
- Enrollment
- 2000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (2)
- Local Institution, Tokyo, Japan
- Medical Data Vision, Inc, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06952465 on ClinicalTrials.govOther trials for DITRA
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07314060A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2, PHASE3NCT06477536Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisShanghai Huaota Biopharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT06433531A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06323356A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisTakeda
- ACTIVE NOT RECRUITINGPHASE3NCT06295692A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisJanssen Pharmaceutical K.K.
- ACTIVE NOT RECRUITINGPHASE4NCT06013969A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated FlaresBoehringer Ingelheim
- RECRUITINGNCT06100991CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness RegistryCorEvitas
- ACTIVE NOT RECRUITINGPHASE2NCT03886246Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous StudyBoehringer Ingelheim